The global bioengineering medicine has entered a new era，and monoclonal antibody drugs have become a rapidly developing segment in the pharmaceutical market. As of the end of 2020，the U.S. FDA has approved a total of 98 antibody drugs，more than 50 types of bioengineered antibody drugs have been sold in China，and the domestic antibody drug market has exceeded the size of 20 billion yuan. With a new round of restructuring under the new normal of China’s pharmaceutical economy，innovative drugs will continue to promote the accelerated growth of the pharmaceutical market.